Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial
Open Access
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis VaccinesJAMA Network Open, 2024
- A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing ageVaccine, 2022
- Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccineseClinicalMedicine, 2021
- Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in ThailandVaccine, 2020
- Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trialVaccine, 2020
- The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine ResponseseClinicalMedicine, 2019
- The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodiesVaccine, 1996
- Serological correlates in whooping coughVaccine, 1993
- Relative efficacy of two acellular pertussis vaccines during three years of passive surveillanceVaccine, 1992
- The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cellsJournal of Biological Standardization, 1985